Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 24, 2015

View Archived Issues

Evestra receives convertible loan from Gedeon Richter to fund women's health pipeline

Palatin Technologies presents concordance analysis of diagnostic criteria for female sexual disorder

Study tests effects of alprostadil cream on genital blood flow

New softgel capsule technology provides better patient experience

Anti-MAdCAM antibody efficacy results for ulcerative colitis and Crohn's disease

Celimmune founded to develop new therapeutics for celiac and other autoimmune diseases

Eli Lilly and Incyte report phase III data for baricitinib in rheumatoid arthritis

Arrowhead begins phase I trial of ARC-AAT

Rindopepimut receives FDA breakthrough therapy designation in glioblastoma

Novocure enrolls first patient in phase II STELLAR trial

Foundation Medicine and H3 Biomedicine to develop precision therapies for cancer

FDA approves Dymista for use in children with seasonal allergic rhinitis

New guanylyl cyclase activators disclosed by Bayer

Rigel and BMS collaborate on TGF-beta receptor inhibitors for cancer

Gruenenthal divulges novel PDE4B inhibitors

Merck & Co. patents new ROMK channel blockers

Retrospective analysis shows overall survival benefit for ThermoDox in a subgroup of HCC patients

Sunshine Lake Pharma discloses new 5-HT reuptake inhibitors

Boehringer Ingelheim presents new ROR-gamma modulators

PMO targeting Ebola virus VP24 protects nonhuman primates

Takeda to acquire select portfolio from Neutec

FDA approves Novartis's panobinostat for multiple myeloma

ValiRx reports preliminary results from a phase I/II trial of VAL-201 in men with prostate cancer

FDA accepts Taiho's NDA for TAS-102 for refractory metastatic colorectal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...